Overview
The goal of this single centre pilot study is to explore whether 18F-fluoro-ethyl-tyrosine PET (FET-PET) yields comparable findings to 11C-methionine PET (Met-PET) for the localisation of pituitary tumours.
Description
Up to 20 patients with pituitary adenomas (PA) who have previously undergone 11C-methionine PET (Met-PET) as part of routine clinical care will undergo 18F-fluoroethyltyrosine PET (FET-PET). Patients with newly diagnosed PA or residual/recurrent pituitary tumours following previous treatment will be eligible for recruitment to the study.
Quantitative and qualitative analyses will be performed to assess whether MET-PET and FET-PET yield comparable findings in patients with newly diagnosed or recurrent PA.
Eligibility
Inclusion criteria
- Participant is willing and able to give informed consent for participation in the study
- Male or female, age 18 or above
- Presence of pituitary adenoma suspected on the basis of clinical/biochemical and/or radiological findings
- Previous 11C-Met-PET/CT
Exclusion criteria
- Inability to give informed consent
- Pregnancy or suspected pregnancy
- Inability to lie supine for 30-60 minutes
- Patient body habitus above scanner dimensions
- Known allergy to intravenous radiographic contrast agents